Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis

Psoriasis is a chronic inflammatory disease characterised by sharply demarcated erythematous and scaly skin lesions accompanied by systemic manifestations. Classified by WHO as one of the most serious non-infectious diseases, psoriasis affects 2-3% of the global population. Mechanistically, psoriatic lesions result from hyperproliferation and disturbed differentiation of epidermal keratinocytes that are provoked by immune mediators of the IL-23 and IL-17 pathway. Translational immunology has had impressive success in understanding and controlling psoriasis. Psoriasis is the first disease to have been successfully treated with therapeutics that directly block the action of the cytokines of this pathway; in fact, therapeutics that specifically target IL-23, IL-17, and IL-17RA are approved for clinical use and show excellent efficacy. Furthermore, inhibitors of IL-23 and IL-17 intracellular signalling, such as TYK2 or ROR gamma t, are in clinical development. Although therapies that target the IL-23 and IL-17 pathway also improve psoriatic arthritis symptoms, their effects on long-term disease modification and psoriasis-associated comorbidities still need to be explored.

Automated summary

Psoriasis is a chronic inflammatory disease affecting 2-3% of the global population, characterized by sharply demarcated erythematous and scaly skin lesions. The disease results from hyperproliferation and disturbed differentiation of epidermal keratinocytes provoked by immune mediators of the IL-23 and IL-17 pathway. Therapeutics targeting IL-23, IL-17, and IL-17RA have shown excellent efficacy in treating psoriasis.